Abstract: Processes are provided for the production of methenamine mandelate that do not require the isolation of produced methenamine prior to production of the methenamine mandelate.

Abstract: The present invention contemplates a high dose finished pharmaceutical dosage form comprising a methenamine salt, such as methenamine mandelate, as an active pharmaceutical ingredient wherein the methenamine salt API has a moisture content that is less than the upper limit specified in the USP. A preferred embodiment of the present invention has a moisture content that is half of the limit set forth in the USP for each particular methenamine salt. An even more preferred embodiment has a moisture content of less than or equal to one-tenth of a percent (0.1%), regardless of the methenamine salt. The present invention may include one or more pharmaceutically acceptable ingredients. The present invention also contemplates a moisture content of the high dose finished pharmaceutical dosage form that is less than one percent.

Abstract: The present invention provides a process that enables a substituted methylamine compound which is useful as an intermediate for the production of agricultural chemicals and medicines, to be produced easily, with good yield, and at low cost, and also provides a production intermediate thereof. The process comprises a step of reacting a hexamethylenetetraammonium salt compound represented by a formula (I) with a base to obtain an N-methylidene-substituted methylamine oligomer represented by a formula (II) or a mixture of two or more of the oligomers, and a step of hydrolyzing the N-methylidene-substituted methylamine oligomer represented by formula (II) or the mixture of two or more of the oligomers in the presence of an acid.

Abstract: The present invention relates to pharmaceutical compositions comprising metal phthalocyanine analogues of formula (I) and metal chelating compounds having a good bioavailability and enhanced photoinactivation properties against Gram negative bacteria; and to their use for in vivolex vivo applications, such as blood and blood derivatives sterilization.

Abstract: A compound of general Formula (I) having histone deacetylase (HDAC) and/or Cyclin-dependent kinase (CDK) inhibitory activity, a pharmaceutical composition comprising the compound, and a method useful to treat diseases using the compound.

Abstract: The present invention provides a compound of general Formula (I) having histone deacetylase (HDAC) and/or Cyclin-dependent kinase (CDK) inhibitory activity, a pharmaceutical composition comprising the compound, and a method useful to treat diseases using the compound.

Abstract: This invention relates to therapeutic methods for treating or preventing an osteoclast-related disease or disorder in a subject identified as in need of a treatment of bone diseases, compounds for such uses, and compositions thereof.

Abstract: Compositions are disclosed comprising novel fluorinated cationic alcohols in a cosmetically acceptable vehicle. The fluorinated compounds alter a surface property of the hair to provide hair conditioning, for example. In embodiments, the compounds have improved water solubility and deposition properties.

Abstract: The present invention relates to new pyrrolyltriazine derivatives of general formula (I) together with method for obtaining them. The physico-chemical properties of said compounds allow them to be used as absorbents of UV radiation.

Abstract: Compounds of the formula (I): wherein Ring A, R1, R3, R4, p, q, and n are as defined within and a pharmaceutically acceptable salts and in vivo hydrolysable esters are described. Also described are processes for their preparation and their use as medicaments, particularly medicaments for producing a cell cycle inhibitory (anti-cell-proliferation) effect in a warm-quest-blooded animal, such as man.

Abstract: The present invention provides novel compounds and pharmaceutical compositions thereof useful in the treatment of pain. The compounds of the present invention are azaadamantanes, azanoradamantanes and azahomoadamantanes.

Abstract: Skin protection agents such as topical compositions which can prevent the passage of toxic chemicals through the skin, such as barrier creams. Formulations may contain hexamethylene tetramine or derivatives or analogues thereof, which react with alkylating agents such as sulfur mustard, and which are suitable for formulation into topical compositions. The formulations additionally may contain perfluorinated polymeric compounds which are effective barrier compounds for a range of toxic chemicals.

Abstract: The present invention relates to acylguanidine derivatives of the formula I in which R1, R2, R4, Ar, X and n have the meanings indicated in the claims, their physiologically tolerable salts and their prodrugs. The compounds of the formula I are valuable pharmacologically active compounds. They are vitronectin receptor antagonists and inhibitors of cell adhesion. They inhibit, for example, bone resorption by osteoclasts and are suitable for the therapy and prophylaxis of diseases which are caused at least partially by an undesired extent of bone resorption, for example osteoporosis. The invention furthermore relates to processes for the preparation of compounds of the formula I, their use, in particular as active ingredients in pharmaceutical preparations, and pharmaceutical preparations comprising them.

Abstract: The 1,5′-bitetrazole of the invention comprises 1,5′-bitetrazole, and ammonia or an amine. The 1,5′-bitetrazole of the invention decomposes sharply and generates a nontoxic gas.

Abstract: The present invention provides novel compounds and pharmaceutical compositions thereof useful in the treatment of pain. The compounds of the present invention are azaadamantanes, azanoradamantanes and azahomoadamantanes.

Abstract: The present invention relates to protection agents, in particular to topical compositions such as barrier creams which can prevent the passage of toxic chemicals and chemical warfare agents through the skin. Formulations contain hexamethylene tetramine derivatives or analogues thereof and perfluorinated polymeric compounds.

Abstract: A blood substitute employs combinations of fluoro or perfluorochemicals capable in the presence of emulsifying agents of forming emulsions stable at room temperature and possessing enhanced oxygen carrying capacity; the invention enables preparation of an improved blood substitute, with improved O.sub.2 carrying capacity and stability, as well as lessened anaphylactoid reaction.

Abstract: The methylated tertiary amines are selectively prepared by reacting a primary or secondary amine, or a nitrile or aminonitrile, including an aminoalcohol, etheramine, a polyamine or fatty polyamine or amidoamine, or amidopolyamine or dinitrile, with hexamethylenetetramine ("HMTA"), under hydrogen pressure at a temperature no greater than about 160.degree. C. and in the presence of a catalytically effective amount of a hydrogenation catalyst, e.g., nickel deposited onto appropriate support substrate therefor.

Abstract: 1,3,5-TRINITROHEXAHYDRO-1,3,5-TRIAZINE (RDX) is prepared in a new simplif and efficient manner which provides near quantitative yield. Our process is based upon the nitration of 3,7-DIACETYL 1,3,5,7 TETRAAZA[3.3.1.]BICYCLONONANE (DAPT).

Abstract: A blood substitute employs combinations of fluoro or perfluorochemicals capable in the presence of emulsifying agents of forming emulsions stable at room temperature and possessing enhanced oxygen carrying capacity; the invention enables preparation of an improved blood substitute, with improved O.sub.2 carrying capacity and stability, as well as lessened anaphylactoid reaction.

Abstract: Method for obtaining an organic polycrystalline material having in particular electro-optical properties, said material obtained and an electro-optical modulator comprising said material.This method includes a stage (1) for preparing a powder having a size grading of 500 to 800 nm of an organic compound having a delocalized system of electrons .pi. and presenting a non-centrosymmetrical crystalline structure, as well as intramolecular load transfer groupings, a stage (2) for drying the powder under vacuum, a stage (3) for pre-pressing the powder under vacuum, and a hot stage (5) for the uniaxial compression of the dried powder under vacuum.This method enables polycrystalline materials to be obtained, said materials comprising elongated monocrystalline grains orientated according to a given direction.

Abstract: Compounds of the formula ##STR1## wherein X is an anion selected from the group consisting of phosphate, borate and molybdate groups, and a method for making these compounds. The compounds are useful in the control of microorganisms in aqueous systems and in the inhibition of corrosion of metal surfaces in contact with aqueous systems.

Abstract: A method of preserving an aqueous system which is susceptible to microbiological degradation, comprising the step of adding to the system a compound having the formula ##STR1## wherein the compound is added in an amount sufficient to inhibit the growth and proliferation of at least one microorganism in the aqueous system.The compound 1-methyl-3,5,7-triaza-1-azoniatricyclodecane triiodide and a method for preparing same comprising the substitution of triiodide anion for a monohalide anion in an aqueous medium.

Abstract: The invention disclosed herein relates to a process for producing heterocyclic ethanolamines, especially 2-(2-furyl)ethanolamine.

Abstract: A method of preserving an aqueous system which is susceptible to microbiological degradation, comprising the step of adding to the system a compound having the formula ##STR1## wherein X is an anion selected from the group consisting of sulfate, acetate and citrate groups, and wherein the compound is added in an amount sufficient to inhibit the growth and proleferation of at least one microogranism in the aqueous system.The compounds 1-methyl-3,5,7-triaza-1-azoniatricyclodecane acetate and 1-methyl-3,5,7-triaza-1-azoniatricyclodecane citrate, and a method for preparing these compounds comprising the reaction of ammonium citrate, or ammonium acetate, with methylamine, formaldehyde and ammonia in an aqueous medium.

Abstract: A blood substitute employs combinations of fluoro or perfluorochemicals capable in the presence of emulsifying agents of forming emulsions stable at room temperature and possessing enhanced oxygen carrying capacity; the invention enables preparation of an improved blood substitute, with improved O.sub.2 carrying capacity and stability, as well as lessened anaphylactoid reaction.

Abstract: N-(heterocyclicaminocarbonyl)arylsulfonamides in which the aryl radical is substituted in the 2-position by a carboxy radical, ester, thioester, or amide thereof; e.g. N-[(4,6-dimethylpyrimidin-2-yl)aminocarbonyl]-2-methoxycarbonylbenzenesulf onamide or N-[(4,6-dimethoxy-1,3,5-triazin-2-yl)aminocarbonyl]-2-methoxycarbonylbenze nesulfonamide; are useful for the regulation of plant growth and as pre-emergence and post-emergence herbicides.

Abstract: The present invention relates to iodopropargyl-ammonium salts of the formula (I) ##STR1## in which R, R.sup.1, R.sup.2 and X.sup..phi. have the meanings given in the description.They are obtained, for example, by reacting tertiary amines with an iodopropargyl halide. In a second reaction step, the halogen anion can be exchanged for other anions, such as phosphate and sulphate. The iodopropargylammonium salts of the formula (I) are distinguished by high activity as pest-combating agents, in particular by a fungicidal as well as bactericidal activity.

Abstract: Catalysts producing a sharply peaked alkoxylation distribution during the alkoxylation of organic materials comprise mixtures of BF.sub.3 and metal alkyls or metal alkoxides, SiF.sub.4 and metal alkyls or metal alkoxides, or mixtures of these catalysts.

Abstract: Hexamethylenetetramine-N-acetyl-thiazolidine-4-carboxylate having formula (I) ##STR1## is endowed with antibacterial and mucosecretolytic properties. These properties along with the very low toxicity of the compound (I) make it particularly suited for the chemotherapeutical treatment of the affections of the urinary and intestinal tracts, and for the treatment of bladder and intestinal catarrhs.

Abstract: A novel association complex in disclosed, formed by the interaction between a hexamethylenetetramine quaternary salt of a halogenated allyl halide and a water-soluble homopolymer of ethylene oxide. The composition is neutral in pH, fluoresces at a characteristic wavelength of 355 nanometers, has unusual moisture retention characteristics, and possesses the unique ability to inhibit viral replication. The composition is preferably used in aqueous solution, and finds utility as a protective moisturizing agent for the skin, as a healing agent for skin injuries, as a germicidal lubricant, and as a medication for topical application to lesions due to viral infections.

Abstract: Disclosed herein is a process for producing dry compositions containing thiocyanic acid and hexamethylene-tetramine wherein hexamethylene-tetramine is reacted with an alkali or alkaline earth metal thiocyanate in the aqueous phase in the presence of acid, and wherein the aqueous reaction product solution, without isolation of the reaction product, is combined with an inert carrier substance and dried.

Abstract: Derivatives of trans-3-hydroxy-4-amino-chroman and pharmaceutical compositions containing such derivatives are useful for effecting vasodilation in mammals, including humans.

Abstract: 3,5,7-Triaza-1-azoniatricyclo(3.3.1.1.sup.3,7)-decane:1-(2-phenoxyethyl)-, bromides are disclosed. These compounds have utility as antimicrobials and herbicides.

Abstract: Pivaloyl benzyl ureas, e.g., 1,1-bis(4-pivaloylbenzyl)-3-methyl urea, are prepared by reacting a corresponding 4",4'"-iminodimethylene-di-tert. alkylophenones with an alkyl isocyanate, and are useful as hypolipidemic agents.

Abstract: Quaternary ammonium salts consisting of cations and anions wherein the cations have the formula: ##STR1## and the anions are halide ions. These salts which are useful as intermediates in the preparation of 3-phenoxybenzaldehyde, may be prepared by reacting a 3-phenoxybenzyl halide with hexamethylenetetramine.

Abstract: A process has been developed for producing complexes of phenol or phenolic compounds and hexamethylenetetramine by mixing the ingredients with only enough water, or other suitable solvent, to promote the reaction. Heat liberated by the reaction is controlled by cooling the mixing chamber, and drying is accomplished by removing the small amount of solvent in conventional type dryers.

Abstract: Compounds of the formula ##STR1## wherein R.sub.3 is hydrogen, halogen, alkyl of 1 to 6 carbon atoms, alkenyl of 2 to 6 carbon atoms, alkoxyl of 1 to 6 carbon atoms, alkenyloxyl of 2 to 6 carbon atoms, alkylthio of 1 to 6 carbon atoms, hydroxyl, amino, alkylamino of 1 to 6 carbon atoms, dialkylamino of 1 to 6 carbon atoms, nitro, trifluoromethyl, acylamino of 2 to 7 carbon atoms, alkoxysulphonylamino of 1 to 6 carbon atoms, carboxyl, nitrile, AOR.sub.4, ASR.sub.7, ASO.sub.2 R.sub.7, ANHR.sub.7, ANR.sub.7 COR.sub.8, ANR.sub.7 SO.sub.2 R.sub.8 or ANR.sub.7 CO.sub.2 R.sub.8, wherein A is alkylene of 1 to 4 carbon atoms, R.sub.7 is alkyl of 1 to 4 carbon atoms and R.sub.8 is alkyl of 1 to 4 carbon atoms;R.sub.4 is hydrogen or halogen; orR.sub.3 together with R.sub.4 forms a --CH.dbd.CH--CH.dbd.CH--, --NH--CH.dbd.CH--, --CH.sub.2 --CH.sub.2 --CH.sub.2 --CH.sub.2 -- or --CH.sub.2 --CH.sub.2 --CH.sub.2 --CO-- system;R.sub.5 is hydrogen, alkyl of 1 to 6 carbon atoms or phenyl; andR.sub.

Abstract: Anti-hypertensive derivatives of trans-3-hydroxy-4-amino-chroman, their preparation from amines and chroman epoxide derivatives, and pharmaceutical compositions containing such anti-hypertensive derivatives for reducing blood pressure in mammals including humans.

Abstract: Adducts of certain unsaturated halides with hexamethylenetetramine are known to be effective germicides when present in concentrations as low as 0.01 percent in water-containing organic mixtures. However, under certain conditions the compounds may undergo detrimental spontaneous exothermic decomposition. Blending with the adduct an additament which undergoes an endothermic change at a temperature below that at which exothermic decomposition of the adduct decomposition thereby providing a composition stabilized for packaging and/or storage.

Abstract: A number of water-soluble, one-to-one quaternary ammonium adducts of unsaturated organic halides and dihalides with hexamethylenetetramine are known as being useful as antimicrobial agents. It has now been discovered that a two-to-one quaternary ammonium adduct can be prepared from hexamethylenetetramine and 3,4-dichlorobutene-1; this two-to-one adduct is a more active, less toxic antimicrobial agent than the known one-to-one quaternary ammonium adducts.